Revisiting the role of therapeutic drug monitoring in optimizing treatment outcomes in patients of bipolar affective disorders receiving lithium therapy: a prospective observational study
DOI:
https://doi.org/10.18203/2349-3933.ijam20203064Keywords:
Bipolar affective disorder, Lithium, Therapeutic drug monitoring, Therapeutic optimization, Young Mania Rating ScaleAbstract
Background: Lithium continues to be considered first-line therapy for treatment of acute mania, acute mixed bipolar disease and long-term prophylaxis of bipolar disorder. Present study was done to study the pattern of drug therapy in bipolar affective disorder patients with special reference to lithium in the routine psychiatric outpatients care setting of a tertiary care teaching hospital as well as to understand the prospect of therapeutic drug monitoring in optimization of lithium therapy based on outcome.
Methods: It was a prospective, non-randomized, observational study of a cohort of subjects who are suffering from bipolar affective disorders and on lithium therapy. Patients were prospectively followed up three monthly for three visits with therapeutic drug monitoring of their plasma lithium level, as and when advised by the treating physician, and pre-formed questionnaires.
Results: Results revealed there was significant improvement in symptoms of patients who were monitored with therapeutic drug monitoring and prescribed lithium therapy in accordance with clinical pharmacological consultation for optimal dosing resulting in optimal benefit to patients.
Conclusions: With regular therapeutic monitoring, optimal target serum lithium levels can be achieved with dosage modifications thereby reducing the risk of toxicity with improved drug compliance. Thus, individualization of dosing and optimization of treatment can be achieved by dependable analytical laboratory services, better psycho-education, family support and overall a disease-based management team approach with the involvement of clinical Pharmacologist to meet the complexities of lithium therapy.
References
Benkert O, Hippius H, Anghelescu I, Davids E, founder G, Lange-Asschenfeldt C, et al. Compendium of psychiatric pharmacotherapy. Heidelberg eBerlin Berlin: Springer; 2013.
Jakobsson E, Argüello-Miranda O, Chiu SW, Fazal Z, Kruczek J, Nunez-Corrales S, et al. Towards a unified understanding of lithium action in basic biology and its significance for applied biology. J Membr Biol. 2017;250(6):587-604.
Shah N, Grover S, Rao GP. Clinical Practice Guidelines for Management of Bipolar Disorder. Indian J Psychiatry. 2017;Suppl S1:51-66.
Gautam S, Jain A, Gautam M, Gautam A, Jagawat T. Clinical practice guidelines for bipolar affective disorder (BPAD) in children and adolescents. Indian J Psychiatry 2019;Suppl S2:294-305.
Gaillot J, Steimer JL, Mallet AJ, Thebault JJ, Bieder A. A priori lithium dosage regimen using population characteristics of pharmacokinetic parameters. J Pharmacokinet Biopharm. 1979 Dec 1;7(6):579-628.
McCreadie RG, McCormick M, Morrison DP. The impact of lithium in South-West Scotland. III. The discontinuation of lithium. British J Psychiatry. 1985;146:77-80.
Mitchell PB. Therapeutic drug monitoring of psychotropic medications. Br J Clin Pharmacol. 2000;49(4):303-12.
Touw DJ, Neef C, Thomson AH, Vinks AA. Cost-effectiveness of therapeutic drug monitoring: a systemic review. Ther Drug Monit. 2005;27:10-7.
Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24(1):1-10.
Grandjean EM, Aubry JM. Lithium: updated human knowledge using an evidence-based approach. Part II: clinical pharmacology and therapeutic monitoring. CNS Drugs. 2009;23:331-49.
Radziwoñ-Zaleska M, Matsumoto H, Skalski M, Wilkowska J, Januszko P, Matoszko D, et al. Therapeutic tricyclic antidepressant drug monitoring in younger and older depressive patients. Pharmacol Rep. 2006;58:501-6.
Kanba S, Kato T, Terao T, Yamada K. Committee for Treatment Guidelines of Mood Disorders, Japanese Society of Mood Disorders, 2012. Guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012. Psychiatry Clin Neurosci. 2013;67:285-300.
Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011 Dec;21(06):195-235.
Young RC, Biggs JT, Ziegler VE, Meyer DA. Young Mania Rating Scale. In: Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000:540-542.
Rapoport SI, Basselin M, Kim HW, Rao JS. Bipolar disorder and mechanisms of action of mood stabilizers. Brain Res Rev. 2009;61(2):185-209.
Judd LL, Hubbard B, Janowsky DS, Huey LY, Attewell PA. The effect of lithium carbonate on affect, mood, and personality of normal subjects. Arch Gen Psychiatry. 1977;34(3):346-51.
Hegerl U, Herrmann WM, Ulrich G, Müller-Oerlinghausen. Effects of lithium on auditory evoked potentials in healthy subjects. B Biol Psychiatry. 1990 Mar 1;27(5):555-60.
Goodwin FK, Jamison KR. Manic-depressive illness. Oxford University Press; 1990.
Talbott JH. Use of lithium salts as a substitute for sodium chloride. Arch Intern Med (Chic). 1950 Jan;85(1):1-10.
Amdisen A. Serum lithium determinations for clinical use. Scand J Clin Lab Invest. 1967;20:104-8.
Burton ME, Shaw LM, Schentag JJ, Evans, WE. Applied Pharmacokinetics & Pharmacodynamics. Baltimore, Philadelphia: Lippincott Williams & Wilkins; 4th ed.; 2006.
Bellack AS, Bowden CL, Bowie CR, Byerly MJ, Carpenter WT, Copeland LA, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009 Sep 25;70(SUPPL. 4):1-48.
Altman S, Haeri S, Cohen LJ, Ten A, Barron E, Galynker II, Duhamel KN. Predictors of relapse in bipolar disorder: a review. J Psychiatr Pract. 2006;12(5):269-82.
Keck Jr PE, McElroy SL, Strakowski SM, Stanton SP, Kizer DL, Balistreri TM, et al. Factors associated with pharmacologic noncompliance in patients with mania. J Clin Psychiatry. 1996;57(7):292-7.
American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(suppl 4):1-50.
Yatham LN, Kennedy SH, O'Donovan C, Parikh S, MacQueen G, McIntyre R, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar disorders. 2005 Jun;7:5-69.
Strickland TL, Lin KM, Fu P, Anderson D, Zheng Y. Comparison of lithium ratio between African-American and Caucasian bipolar patients. Biol Psychiatry. 1995;37:325-30.
Honda Y, Suzuki T. Transcultural pharmacokinetic study on Li concentration in plasma and saliva. Psychopharmacol. Bull. 1979;15:37-9.
